Companies › Hope Biosciences
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology, Genitourinary; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Autologous HB-adMSCs Autologous adipose-derived mesenchymal stem cells | – | Phase 2 | Traumatic Brain Injury | Dec 2027 |
| Allogeneic HB-adMSCs Allogeneic adipose-derived mesenchymal stem cells | – | Phase 1 | Acute Kidney Injury | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05951777 | Autologous HB-adMSCs | Phase 2 | Traumatic Brain Injury | Oncology | Dec 2027 |
| NCT06654193 | Allogeneic HB-adMSCs | Phase 1 | Acute Kidney Injury | Genitourinary | Jan 2028 |
No annotated target.
–
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Hrain Biotechnology Marzieh Ebrahimi Beijing Yongtai Ruike Biotechnology Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.